Virbac stock slips after strong H1 2026 growth and margin gains
Published on 09/19/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Virbac stock (ISIN FR0000031577) traded lower on Euronext Paris on September 18, 2026 despite the French animal health group reporting solid first-half 2026 growth and profitability, including 7.4 percent organic revenue expansion and an adjusted EBIT margin of 18.8 percent at constant exchange rates and scope.
Half-year 2026 figures show solid growth
According to a summary of Virbac's first-half 2026 results published by Investing.com on September 18, 2026, Virbac generated revenue of EUR 768.0 million in H1 2026, up 7.4 percent at constant exchange rates and scope compared with the first half of 2025.
In the same overview, adjusted EBIT reached EUR 144.2 million in H1 2026, corresponding to an adjusted EBIT margin of 18.8 percent, which represents an improvement of 0.5 percentage points versus H1 2025 as the margin rose from 18.3 percent a year earlier.Fortuneo Bourse
The same H1 2026 figures show consolidated net income of EUR 87.1 million, up about 5.9 percent compared with EUR 82.3 million in the first half of 2025, underscoring that earnings are growing slightly faster than revenue.Fortuneo Bourse
Guidance and margins support the investment case
As an earnings-call recap on Yahoo Finance reported on September 18, 2026, Virbac's management reaffirmed its full-year 2026 guidance following the half-year release, now targeting the upper end of 5.5 to 7.5 percent revenue growth at constant exchange rates and scope and aiming for an adjusted EBIT margin of around 17 percent for the full year.
The same earnings-call summary notes that net income in H1 2026 rose 6 percent to EUR 87.1 million and that capital expenditure for 2026 is expected to reach about EUR 125 million, while cash generation is projected at roughly EUR 80 million, highlighting the group's ongoing investments in manufacturing capacity, R&D and growth platforms alongside solid cash flow.Investing.com
An analysis published on September 18, 2026 by Simply Wall St underscores that H1 2026 revenue of approximately EUR 768 million and an adjusted EBIT margin of 18.8 percent place Virbac among the more profitable animal health specialists, even as the company continues to invest heavily in its Supercharge product platforms and capacity expansion.
Share reaction and analyst view
Despite the improved margins and confirmed guidance, Virbac stock moved lower on the half-year figures. As Ideal-investisseur reported on September 18, 2026, the shares fell about 5.25 percent intraday to EUR 298.00, significantly underperforming the SBF 120 index, which was down 0.73 percent over the same period.
The same report highlights that Virbac's monthly share-price decline had reached 9.42 percent by mid-September 2026, reflecting a downward trend in place for several weeks and showing that the market is cautious despite the better fundamentals and guidance.Ideal-investisseur
In that same Ideal-investisseur piece, CIC Market Solutions confirmed its analyst opinion to buy Virbac and maintained a price target of EUR 400.00 on September 18, 2026; with the share around EUR 298.00 during the session, this target implied an upside potential of about 34 percent, signalling that at least one covering house sees the recent weakness as an opportunity.
Stock level and valuation context
Per closing data from Euronext Paris relayed by Boursorama for September 18, 2026, Virbac stock closed at EUR 310.50, down 1.27 percent from the previous day's close of EUR 314.50, with an intraday high of EUR 314.50 and a low of EUR 297.00 in that session.
The same Boursorama overview shows that, at this closing level, Virbac shares were trading near the lower end of their recent 52-week trading band, with the intraday low of EUR 297.00 on September 18, 2026 only slightly above the quoted 52-week low, while the 52-week high stood at about EUR 385.50 in earlier trading, leaving the stock roughly 19.5 percent below that peak.
For investors, the combination of high teens EBIT margins in H1 2026, guidance that points to continued mid-single to high-single-digit revenue growth, and a share price positioned closer to the 52-week low than the high frames Virbac stock as a case where execution is currently strong but market expectations remain cautious, partly due to concerns over margin normalization and elevated capital expenditure.
Virbac stock price and market data
As of September 18, 2026, the reference price for Virbac stock on its primary listing venue Euronext Paris was EUR 310.50, representing a 1.27 percent decline versus the prior close of EUR 314.50, with trading volume on that day in the tens of thousands of shares and the stock changing hands within a range from EUR 297.00 to EUR 314.50.
Virbac stock at a glance
- Company: Virbac SA
- ISIN: FR0000031577
- Ticker: VIRP
- Trading venue: Euronext Paris
- Price (as of September 18, 2026, 17:35): 310.50 EUR
- Market capitalization: approximately 2.6 billion EUR (as of September 18, 2026)
- Sector / Industry: Pharmaceuticals - Animal Health
- Index membership: SBF 120
